| (3S,5R)-fluvastatin | multiple interactions | ISO | RGD:1342473 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA | CTD | PMID:16996129 |
| 17beta-estradiol | affects expression | ISO | RGD:10534 | 6480464 | Estradiol affects the expression of ERCC5 mRNA | CTD | PMID:15721199 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:10534 | 6480464 | Tetrachlorodibenzodioxin affects the expression of ERCC5 mRNA | CTD | PMID:21570461 |
| 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2,4-dinitrotoluene affects the expression of ERCC5 mRNA | CTD | PMID:21346803 |
| 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2,6-dinitrotoluene affects the expression of ERCC5 mRNA | CTD | PMID:21346803 |
| 4-hydroxynon-2-enal | decreases expression | ISO | RGD:1342473 | 6480464 | 4-hydroxy-2-nonenal results in decreased expression of ERCC5 mRNA | CTD | PMID:12419474 |
| acetylsalicylic acid | increases expression | ISO | RGD:1342473 | 6480464 | Aspirin results in increased expression of ERCC5 mRNA | CTD | PMID:11906190 |
| aflatoxin B1 | increases expression | ISO | RGD:10534 | 6480464 | Aflatoxin B1 results in increased expression of ERCC5 mRNA | CTD | PMID:19770486 |
| arsenic atom | increases expression | ISO | RGD:1342473 | 6480464 | Arsenic results in increased expression of ERCC5 mRNA | CTD | PMID:11134558 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:10534 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in increased expression of ERCC5 mRNA | CTD | PMID:21715664 |
| benzo[a]pyrene | increases expression | ISO | RGD:10534 | 6480464 | Benzo(a)pyrene results in increased expression of ERCC5 mRNA | CTD | PMID:19770486 more ... |
| benzo[a]pyrene | increases expression | ISO | RGD:1342473 | 6480464 | Benzo(a)pyrene results in increased expression of ERCC5 protein | CTD | PMID:19748547 |
| benzo[a]pyrene | increases expression | ISO | RGD:10534 | 6480464 | Benzo(a)pyrene results in increased expression of ERCC5 mRNA | CTD | PMID:21715664 PMID:19770486 |
| benzo[a]pyrene | increases expression | ISO | RGD:10534 | 6480464 | Benzo(a)pyrene results in increased expression of ERCC5 mRNA | CTD | PMID:19770486 PMID:21715664 |
| benzo[a]pyrene | increases expression | ISO | RGD:10534 | 6480464 | Benzo(a)pyrene results in increased expression of ERCC5 mRNA | CTD | PMID:21715664 |
| C60 fullerene | decreases expression | EXP | | 6480464 | fullerene C60 results in decreased expression of ERCC5 mRNA | CTD | PMID:19167457 |
| cadmium dichloride | multiple interactions | ISO | RGD:1342473 | 6480464 | [sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC5 mRNA | CTD | PMID:12634122 |
| cadmium dichloride | increases expression | ISO | RGD:10534 | 6480464 | Cadmium Chloride results in increased expression of ERCC5 mRNA | CTD | PMID:20883709 |
| cisplatin | decreases response to substance | ISO | RGD:1342473 | 6480464 | ERCC5 mRNA results in decreased susceptibility to Cisplatin | CTD | PMID:21452186 |
| cisplatin | multiple interactions | ISO | RGD:1342473 | 6480464 | ERCC5 mutant form inhibits the reaction [RRM2 mutant form promotes the reaction [TP53 mutant form promotes the reaction [Cisplatin results in increased phosphorylation of H2AFX protein]]] | CTD | PMID:21875941 |
| copper(2+) sulfate | decreases expression | ISO | RGD:1342473 | 6480464 | Copper Sulfate results in decreased expression of ERCC5 mRNA | CTD | PMID:19549813 |
| daidzein | affects expression | ISO | RGD:10534 | 6480464 | daidzein affects the expression of ERCC5 mRNA | CTD | PMID:15721199 |
| diazinon | decreases expression | ISO | RGD:1342473 | 6480464 | Diazinon results in decreased expression of ERCC5 mRNA | CTD | PMID:16539210 |
| dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of ERCC5 mRNA | CTD | PMID:21266533 |
| dichromium trioxide | multiple interactions | ISO | RGD:1342473 | 6480464 | [sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC5 mRNA | CTD | PMID:12634122 |
| diethylstilbestrol | affects expression | ISO | RGD:10534 | 6480464 | Diethylstilbestrol affects the expression of ERCC5 mRNA | CTD | PMID:15721199 |
| hydrogen peroxide | multiple interactions | ISO | RGD:1342473 | 6480464 | [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of ERCC5 protein | CTD | PMID:18951874 |
| hydroxyurea | increases expression | ISO | RGD:10534 | 6480464 | Hydroxyurea results in increased expression of ERCC5 mRNA | CTD | PMID:12929121 |
| imiquimod | increases expression | ISO | RGD:10534 | 6480464 | imiquimod results in increased expression of ERCC5 mRNA | CTD | PMID:21878529 |
| kojic acid | multiple interactions | ISO | RGD:10534 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA | CTD | PMID:17917374 |
| L-ascorbic acid | multiple interactions | ISO | RGD:10534 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA | CTD | PMID:17917374 |
| lead diacetate | multiple interactions | ISO | RGD:1342473 | 6480464 | [sodium arsenite co-treated with Cadmium Chloride co-treated with chromium oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC5 mRNA | CTD | PMID:12634122 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:10534 | 6480464 | [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA | CTD | PMID:17917374 |
| N-nitrosodiethylamine | multiple interactions | ISO | RGD:10534 | 6480464 | RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of ERCC5 mRNA] | CTD | PMID:17854601 |
| N-nitrosodiethylamine | increases expression | ISO | RGD:10534 | 6480464 | Diethylnitrosamine results in increased expression of ERCC5 mRNA | CTD | PMID:17854601 |
| paclitaxel | increases expression | ISO | RGD:10534 | 6480464 | Paclitaxel results in increased expression of ERCC5 mRNA | CTD | PMID:12929121 |
| phenethyl isothiocyanate | increases expression | ISO | RGD:1342473 | 6480464 | phenethyl isothiocyanate results in increased expression of ERCC5 mRNA | CTD | PMID:20442190 |
| pirinixic acid | decreases expression | ISO | RGD:10534 | 6480464 | pirinixic acid results in decreased expression of ERCC5 mRNA | CTD | PMID:17950772 |
| pirinixic acid | multiple interactions | ISO | RGD:10534 | 6480464 | PPARA protein promotes the reaction [pirinixic acid results in decreased expression of ERCC5 mRNA]; more ... | CTD | PMID:17950772 |
| quercetin | decreases expression | ISO | RGD:1342473 | 6480464 | Quercetin results in decreased expression of ERCC5 mRNA | CTD | PMID:21632981 |
| rel-(3R,5S)-fluvastatin | multiple interactions | ISO | RGD:1342473 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA | CTD | PMID:16996129 |
| staurosporine | affects expression | ISO | RGD:10534 | 6480464 | Staurosporine affects the expression of ERCC5 mRNA | CTD | PMID:15721199 |
| sulforaphane | increases expression | ISO | RGD:1342473 | 6480464 | sulforafan results in increased expression of ERCC5 mRNA | CTD | PMID:20442190 |
| sulindac | decreases expression | ISO | RGD:1342473 | 6480464 | Sulindac results in decreased expression of ERCC5 mRNA | CTD | PMID:11906190 |
| tert-butyl hydroperoxide | decreases expression | ISO | RGD:1342473 | 6480464 | tert-Butylhydroperoxide results in decreased expression of ERCC5 mRNA | CTD | PMID:12419474 |
| theophylline | multiple interactions | ISO | RGD:1342473 | 6480464 | [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of ERCC5 protein | CTD | PMID:18951874 |
| zoledronic acid | multiple interactions | ISO | RGD:1342473 | 6480464 | [zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA | CTD | PMID:16996129 |